DXCM vs PHG
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DXCM · DexCom$79.32 ▼ 1.08%
PHG · Royal Philips$28.61 ▼ 2.19%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DXCM +27.5%
- PHG +8.7%
Head to head
| Metric | DXCM | PHG |
|---|---|---|
| Price | $79.32 | $28.61 |
| Change today | ▼ 1.08% | ▼ 2.19% |
| Market cap | $29.58B | $27.97B |
| Return, 3 months | -12.9% | +4.0% |
| Return, year to date | +19.5% | +9.8% |
| Return, 1 year | +31.7% | +9.1% |
| P/E (TTM) | 31.2 | 26.3 |
| P/B | 11.7 | 2.2 |
| P/E percentile vs own 5y | 6th | 82nd |
| Dividend yield | – | 3.44% |
| Revenue growth (YoY, latest qtr) | +11.2% | +2.1% |
| Net profit growth (YoY) | -3.1% | -85.0% |
| Gross margin | 63.4% | 46.4% |
| Operating margin | 24.0% | 8.9% |
| Net margin | 19.4% | 5.4% |
| Return on equity | 37.7% | 8.6% |
| Analyst target vs. price | +25.1% | – |
| Analyst buy share | 93% | 0% |
| RSI (14) | 43 | 51 |
| 30-day volatility | 45.7% | 33.7% |
| Max drawdown, 1 year | -22.6% | -24.8% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DXCM is the largest of the group by market value.
- DXCM has returned the most over the past year.
- PHG carries the lowest trailing P/E.
- DXCM is growing revenue fastest.
- DXCM keeps the most profit per dollar of sales.
- PHG has been the calmest stock over the last 30 days.